Loading stock data…
Altimmune (ALT)
$2.77-0.07 (-2.46%)
Market ClosedLast close Jul 24
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Altimmune, Inc. in the Healthcare sector is trading at $2.77 with a market capitalization of $509M. Wall Street consensus targets $16.89 (9 analysts), implying a +509.7% move over the next 12 months. The stock is currently near its 52-week low of $2.56, remaining 26.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +509.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $26,000↑ | $5,000 | $5,000 | $5,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$24.24M↑ | -$28.89M↓ | -$20.86M↑ | -$22.92M↓ | -$21.82M |
| Net Income | -$22.56M↑ | -$27.36M↓ | -$19.01M↑ | -$22.15M↓ | -$19.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$508.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.07%
Volume
Today's trading volume
1.86M
Recent News
US Research house initiates Solvonis coverage citing differentiated addiction strategy
Water Tower Research has initiated coverage of Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF), the London-listed biopharmaceutical company developing ketamine-based treatments for alcohol use disorder. Analysts framed Solvonis as a late clinical-stage company trading at a microcap valuation...
Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market
Altimmune, Inc. (NASDAQ:ALT), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. Fresh analyst confidence in the company’s MASH drug candidate follows strong data that continues to build the case for pemvidutide. On June 22, 2026, Leerink analyst Thomas Smith initiated coverage of Altimmune, Inc. (NASDAQ:ALT) with an “Outperform” […]
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Altimmune, Inc. (NASDAQ:ALT) is one of the best weight loss drugs on this list. TheFly reported on May 18 that H.C. Wainwright reiterated its Buy rating on ALT while reducing its price objective from $25 to $20. The adjustment was […]